Silexion Therapeutics (NASDAQ:SLXN) Issues Quarterly Earnings Results

Silexion Therapeutics (NASDAQ:SLXN) issued its quarterly earnings results on Thursday. The company reported ($13.70) EPS for the quarter, topping the consensus estimate of ($218.40) by $204.70, FiscalAI reports.

Silexion Therapeutics Price Performance

Shares of NASDAQ SLXN traded down $0.57 during mid-day trading on Thursday, hitting $2.66. The company had a trading volume of 70,729 shares, compared to its average volume of 135,559. The business’s 50-day simple moving average is $5.83 and its 200-day simple moving average is $142.68. Silexion Therapeutics has a 12 month low of $2.57 and a 12 month high of $777.12. The firm has a market cap of $617,120.00, a P/E ratio of -0.06 and a beta of -0.30.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on SLXN shares. Maxim Group cut Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 29th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Silexion Therapeutics in a research report on Friday, September 11th. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold”.

About Silexion Therapeutics

Silexion Therapeutics Ltd. (NASDAQ: SLXN) is an Israel-based clinical-stage biotechnology company developing RNA-based medicines for the treatment of solid tumors driven by mutations in the KRAS oncogene. The company’s technology is designed to selectively silence cancer-causing KRAS mutations while limiting exposure to healthy tissue. Silexion’s lead program, siG12D-LODER, is an investigational RNA interference therapy targeting the KRAS G12D mutation, which is frequently found in pancreatic and other difficult-to-treat cancers.